TuHURA BIOSCIENCES, INC./NV Net Change in Cash
TuHURA BIOSCIENCES, INC./NV (HURA) reported Net Change in Cash of -$2.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $2.68M.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$6.44M, a 908.25% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-09-30 was -$1.89M.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $796.46K.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$9.04M, a 200.50% decline from fiscal 2024.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $8.99M.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $3.37M.
- TuHURA BIOSCIENCES, INC./NV cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$10.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.62M 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $2.68M 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | -$9.04M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$9.96M 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | -$4.14M 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | -$6.44M 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | $8.99M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$1.89M 10-Q · filed 2024-11-14 | $15.93M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $8.65M 10-Q · filed 2025-08-14 | $3.37M 10-K · filed 2024-10-07 | |||
| 2024-03-31 | $796.46K 10-Q · filed 2025-05-15 | $4.82M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | -$877.00K 10-Q · filed 2024-02-14 | -$10.59M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$1.32M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$10.24M 10-K · filed 2024-10-07 | ||||
| 2023-03-31 | -$8.73M 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | -$6.91M 10-Q · filed 2024-02-14 | ||||
| 2022-09-30 | -$4.70M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $1.24M 10-K · filed 2023-09-18 | ||||
| 2022-03-31 | -$1.70M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $3.53M 10-Q · filed 2023-02-14 | ||||
| 2021-09-30 | $8.80M 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $8.14M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $13.33M 10-Q · filed 2022-05-13 | ||||
| 2020-12-31 | $14.77M 10-Q · filed 2022-02-11 | ||||
| 2020-09-30 | $20.21M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$1.33M 10-K · filed 2021-09-28 | -$1.33M 10-K · filed 2020-09-18 | |||
| 2020-03-31 | $1.25M 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $2.63M 10-Q · filed 2021-02-12 | ||||
| 2019-09-30 | $4.34M 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | -$2.25M 10-K · filed 2020-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |